Acerinox (ACX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
8 May, 2026Opening remarks and agenda
The meeting was convened with both in-person and remote attendance, confirming legal and statutory requirements for validity.
The agenda was made available to shareholders in advance, with no supplements or alternative resolutions submitted.
A notary was present to draw up the official minutes, and the final quorum reached 66.96% of share capital.
Financial performance review
2025 revenues reached EUR 5.8 billion, a 7% increase year-over-year, with adjusted EBITDA at EUR 422 million.
Net income for 2025 was EUR 202.3 million; operating cash flow rose 55% to EUR 455 million.
Working capital improved by EUR 406 million, and net financial debt stood at EUR 1.2 billion.
Share price closed 2025 at EUR 12.66, up 34% annually, with 78% of analysts recommending a buy.
Board and executive committee updates
Board composition changes included reduced director terms to 2 years and reorganization of committees for efficiency.
New policies on code of conduct, whistleblowing, and gender representation were implemented.
The board launched reviews of cybersecurity and AI policies, with updates expected next year.
Latest events from Acerinox
- Adjusted EBITDA up 18% sequentially to €119M, with resilient performance amid global uncertainty.ACX
Q1 20268 May 2026 - Net sales up 7%, adjusted EBITDA €422M, strong cash flow, Haynes integration, recovery ahead.ACX
Q4 202527 Feb 2026 - Q2 EBITDA of €125M and net debt reduction show resilience despite market and strike challenges.ACX
Q2 20243 Feb 2026 - Q3 EBITDA was €114 million; Bahru sale and Haynes deal to lift Q4 amid weak demand.ACX
Q3 202418 Jan 2026 - 2024 marked transformation with Haynes acquisition, Bahru sale, and resilient financials.ACX
Q4 202415 Dec 2025 - Strategic investments and sustainability drive future growth as all AGM proposals are approved.ACX
AGM 202519 Nov 2025 - Q1 EBITDA reached €102M with strong cash flow and Q2 outlook improving.ACX
Q1 202519 Nov 2025 - Q2 EBITDA up 10% sequentially, but H1 profit fell on European weakness and tax impairment.ACX
Q2 202513 Nov 2025 - Q3 EBITDA €108M, cash flow strong, but demand weak; Q4 outlook cautious amid market headwinds.ACX
Q3 20253 Nov 2025